Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

StageZero Life Sciences Ltd T.SZLS

Alternate Symbol(s):  SZLSF

StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is engaged in improving the early detection and management of cancer and other chronic diseases through diagnostics and telehealth programs that provide clinical interventions to assist patients who have cancer (COC Protocol), and help patients reduce the risk of developing late-stage disease (AVRT). Its test, Aristotle, is the first mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle uses mRNA technology to identify the molecular signatures of multiple cancer types and is built on the Company's patented technology platform, the Sentinel Principle. The Care Oncology Clinic offers a supervised treatment regimen (the COC Protocol) for people diagnosed with cancer of any type or stage. Its ColonSentry is a proprietary blood test for screening for Colorectal Cancer.


TSX:SZLS - Post by User

Bullboard Posts
Post by wildbird1on Jan 30, 2019 11:19am
106 Views
Post# 29296180

Follow-up Phone calls...

Follow-up Phone calls...Found this old editorial dated February 25, 2015 by Jeff Engelabout Exas:US Poop test... (https://xconomy.com/wisconsin/2015/02/25/exact-sciences-stock-stumble-on-early-cologuard-launch-data/) Jeff Engel said (QUOTE)''Meanwhile, about 75% of patients who were prescribed Cologuard last year followed through and completed the at-home test, which involves shipping a stool stample to Exact's lab for analysis. Most of them needed a little coaxing from Exact, however, in the form of follow-up phone calls(End of Quote). Genenews simple blood tests will not have a need for a follow-up phone calls. This should make it easier for High Risk Employees(Firefighters).
Bullboard Posts